Skip to content
USPeptideRxLearnApply for an account

Operator Q&A

Can I order compounded medications for patients in another state?

USPeptideRx EditorialLast reviewed:

Yes for patient-specific prescriptions — the federal exemption turns on a valid prescription for an identified individual patient, not on where that patient lives. Two things do change across a state line: the pharmacy has to be licensed by the state it is shipping into, and if you want office-use stock rather than patient-specific fulfilment, the governing rule is the one in the state where the stock will sit.

What federal law actually conditions on

21 U.S.C. § 353a(a) exempts a compounded drug from new drug approval, current good manufacturing practice and adequate-directions requirements when it is "compounded for an identified individual patient based on the receipt of a valid prescription order." The condition is the prescription and the identified patient. Nothing in that clause keys on the patient's state, and nothing in it changes when a prescriber in one state writes for a patient in another.

Louisiana makes a related point about scope: its compounding standards apply "regardless of the location of the patient, e.g., home, hospital, nursing home, hospice, or practitioner's office."

What changes when the pharmacy is outside the patient's state

Licensure. In both states where the nonresident provisions were read, the state regulates out-of-state pharmacies doing business there and measures its own limits against that in-state business.

Louisiana caps non-patient-specific practitioner-administered compounds at 5% of a pharmacy's total dosage units, calculated monthly, then says: "For those Louisiana-licensed pharmacies located outside Louisiana, the total amount distributed and/or dispensed shall reference the pharmacy's total business within the state of Louisiana." Louisiana licenses out-of-state pharmacies and applies its cap to their Louisiana volume alone.

Ohio publishes a separate guidance document for nonresident pharmacies compounding into the state, and its 72-hour product-quality reporting duty applies to nonresident pharmacies as well as in-state ones.

Which state's office-use rule applies

The rules are written as limits on distribution and on the practitioner who receives it, not on where the pharmacy happens to sit. Georgia's says "the distribution of non-patient specific compounded preparations for office use by a practitioner, excluding veterinarians, is prohibited." New Jersey's bars preparing compounded sterile and non-sterile preparations for a licensed prescriber to use in practice absent a patient-specific prescription. A pharmacy in another state does not get a different answer for stock going to a practice in those states.

North Carolina shows the same reach on the compliance side: its annual NABP e-Profile Connect update, due between January 1 and March 31, is triggered by compounding "for any patient or person, in or outside NC."

Can the pharmacy ship to my partner clinics?

Not as resale, and in Illinois not as a sale to a clinic at all outside the office-use subsection. North Carolina states flatly that "compounded drug preparations shall not be offered to other entities for resale." Illinois prohibits sales of compounded drugs to other pharmacies not under common ownership, or to clinics, hospitals or manufacturers, other than as provided in its non-sterile office-use subsection, with a narrow carve-out for contracted centralised prescription filling.

The compounded preparation is meant to reach a named patient, and moving it through an intermediate business is where these two rules stop it.

What this means for your practice

The design that survives in every state read is patient-specific fulfilment: a prescription for a named patient, filled by a pharmacy licensed in that patient's state, shipped to the patient or to the practice for administration. Office-use stock is the part that has to be re-answered state by state, and in Georgia, New Jersey and Louisiana it is closed. Get the office-use position for every state where stock would sit before you scale a routing design — the state-by-state office-use guide quotes each rule verbatim.

What this page does not establish

  • Prescriber licensure across state lines — medical, nursing and telehealth practice acts — is outside this research entirely. Check the medical or nursing board in each state where your patients are.
  • Nonresident pharmacy licensure provisions have been read in Louisiana and Ohio only. The pattern should not be assumed for any other state.
  • Wholesale drug distributor licensure was checked only in Illinois, where it is one of two conditions for a pharmacy to supply sterile office-use stock.
  • The New Jersey rule text is verified current as of a January 2025 capture and is self-dated May 2024.
  • Nothing here describes any drug’s safety or effectiveness.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.

  1. [1]21 U.S.C. § 353a — Pharmacy compounding (Cornell LII)
  2. [2]La. Admin. Code tit. 46, pt. LIII, §§ 2531(B), 2535(E) — Compounding of Drugs
  3. [3]Ohio Board of Pharmacy — Non-Resident Pharmacy Compounding in Ohio
  4. [4]21 NCAC 46 .2801(b), (h), (j) — North Carolina Board of Pharmacy rules
  5. [5]68 Ill. Adm. Code 1330.640 — Pharmaceutical Compounding Standards
  6. [6]Ga. Comp. R. & Regs. r. 480-11-.02(1)(d) — Pharmaceutical Compounding
  7. [7]N.J.A.C. 13:39-11.18 and 13:39-11A.6 — State Board of Pharmacy (archived capture, 2025-01-21)